Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris <i>In Vitro</i>-Reference-Cited by-同舟云学术

Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro

Published:2023-06-15 Issue:6 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

John Larissa L.H.¹^ORCID,Thomson Darren D.¹,Bicanic Tihana¹²³^ORCID,Hoenigl Martin⁴⁵⁶,Brown Alistair J.P.¹^ORCID,Harrison Thomas S.¹²³,Bignell Elaine M.¹^ORCID

Affiliation:

1. Medical Research Council Centre for Medical Mycology, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, United Kingdom

2. Institute of Infection and Immunity, St George’s University of London, Cranmer Terrace, London, United Kingdom

3. Clinical Academic Group in Infection and Immunity, St George’s University Hospitals NHS Foundation Trust, Cranmer Terrace, London, United Kingdom

4. Division of Infectious Diseases, Medical University of Graz, Austria

5. BioTechMed, Graz, Austria

6. Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria

Abstract

Candida auris is an emerging, multidrug-resistant fungal pathogen that causes refractory colonization and life-threatening, invasive nosocomial infections. The high proportion of C. auris isolates that display antifungal resistance severely limits treatment options.

Funder

Medical Research Foundation UK

Medical Research Council Centre for Medical Mycology

UKRI | Biotechnology and Biological Sciences Research Council

UKRI | Medical Research Council

UKRI | Medical Research Council (MRC) Doctoral Training Grant

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01645-22